The IARC convened a Working Group of experts in Lyon, France, on April 2-8, 1997 to evaluate the @entity5 -preventive activity of four nonsteroidal anti-inflammatory drugs ( @entity117 , sulindac, @entity5230 , and @entity3352 ). Epidemiological observational studies of @entity117 that differed in design, location, population, and motivating hypothesis have consistently shown that regular use lowers the risk for @entity14 by up to 50%; however, the one randomized trial did not show protection by @entity117 . Definite evidence of chemopreventive activity normally requires data from appropriately designed randomized trials. The strength of the scientific evidence that @entity117 prevents @entity14 in @entity1 was thus considered to be limited. In animal models, there was sufficient evidence that @entity117 prevented against @entity5 . @entity117 and @entity117 -like drugs may have an important adverse side effects, the most frequent of which are @entity344 ranging in severity from @entity2210 to peptic ulcer. Given the remaining uncertainties in the preventive effect and the risk of adverse side effects, detailed consideration of the total benefits and of @entity137 will be required before widespread use of @entity117 for the prevention of @entity14 can be recommended. Sulindac shows promise in reducing the number and size of @entity6523 in @entity1 with @entity1412 . Further research is required, however, to determine whether and to what extent the risk for @entity14 in such @entity1 is reduced. In @entity1 without @entity1412 , there is inadequate evidence that sulindac has @entity5 -preventive activity. Fewer data were available on @entity5230 and @entity3352 than on @entity117 and sulindac. Although these drugs consistently prevent @entity14 in experimental animal models, the evidence that they prevent @entity14 in @entity1 was considered to be inadequate. The results of the meeting, including recommendations for future research, will be published as Volume 1 of the IARC Handbooks of @entity5 Prevention.

An international evaluation of the XXXX -preventive potential of nonsteroidal anti-inflammatory drugs.

@entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'people'] @entity5230 :: ('MESH:D010894', 'Chemical') :: ['piroxicam'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disturbances'] @entity6523 :: ('MESH:D018256', 'Disease') :: ['adenomatous polyps'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancers', 'colorectal cancer'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['familial adenomatous polyposis']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
